310 related articles for article (PubMed ID: 33722778)
1. Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis.
Kulkarni AV; Tevethia HV; Arab JP; Candia R; Premkumar M; Kumar P; Sharma M; Reddy DN; Padaki NR
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101675. PubMed ID: 33722778
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
3. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
4. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
Zhao J; Li B; Zhang K; Zhu Z
Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy of obeticholic acid and ursodeoxycholic acid in patients with primary biliary cholangitis who respond incompletely to ursodeoxycholic acid: a systematic review.
Li X; Liao M; Pan Q; Xie Q; Yang H; Peng Y; Li Q; Qu J; Chai J
Eur J Gastroenterol Hepatol; 2020 Sep; 32(9):1116-1122. PubMed ID: 32649329
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
7. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
[TBL] [Abstract][Full Text] [Related]
8. Obeticholic acid in primary biliary cholangitis: where we stand.
Manne V; Kowdley KV
Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
[TBL] [Abstract][Full Text] [Related]
9. Primary biliary cholangitis: Old and novel therapy.
Floreani A; Mangini C
Eur J Intern Med; 2018 Jan; 47():1-5. PubMed ID: 28669591
[TBL] [Abstract][Full Text] [Related]
10. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.
Samur S; Klebanoff M; Banken R; Pratt DS; Chapman R; Ollendorf DA; Loos AM; Corey K; Hur C; Chhatwal J
Hepatology; 2017 Mar; 65(3):920-928. PubMed ID: 27906472
[TBL] [Abstract][Full Text] [Related]
11. Real-world experience with obeticholic acid in patients with primary biliary cholangitis.
D'Amato D; De Vincentis A; Malinverno F; Viganò M; Alvaro D; Pompili M; Picciotto A; Palitti VP; Russello M; Storato S; Pigozzi MG; Calvaruso V; De Gasperi E; Lleo A; Castellaneta A; Pellicelli A; Cazzagon N; Floreani A; Muratori L; Fagiuoli S; Niro GA; Feletti V; Cozzolongo R; Terreni N; Marzioni M; Pellicano R; Pozzoni P; Baiocchi L; Chessa L; Rosina F; Bertino G; Vinci M; Morgando A; Vanni E; Scifo G; Sacco R; D'Antò M; Bellia V; Boldizzoni R; Casella S; Omazzi B; Poggi G; Cristoferi L; Gerussi A; Ronca V; Venere R; Ponziani F; Cannavò M; Mussetto A; Fontana R; Losito F; Frazzetto E; Distefano M; Colapietro F; Labanca S; Marconi G; Grassi G; Galati G; O'Donnell SE; Mancuso C; Mulinacci G; Palermo A; Claar E; Izzi A; Picardi A; Invernizzi P; Carbone M; Vespasiani-Gentilucci U;
JHEP Rep; 2021 Apr; 3(2):100248. PubMed ID: 33681748
[TBL] [Abstract][Full Text] [Related]
12. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
[TBL] [Abstract][Full Text] [Related]
13. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
15. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
Wong LL; Hegade VS; Jones DEJ
Dig Dis; 2017; 35(4):359-366. PubMed ID: 28468009
[TBL] [Abstract][Full Text] [Related]
16. Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
Alkhouri N; LaCerte C; Edwards J; Poordad F; Lawitz E; Lee L; Karan S; Sawhney S; Erickson M; MacConell L; Zaru L; Chen J; Campagna J
Liver Int; 2024 Apr; 44(4):966-978. PubMed ID: 38293761
[TBL] [Abstract][Full Text] [Related]
17. Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders.
Fiorucci S; Di Giorgio C; Distrutti E
Handb Exp Pharmacol; 2019; 256():283-295. PubMed ID: 31201552
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid.
Gomez E; Garcia Buey L; Molina E; Casado M; Conde I; Berenguer M; Jorquera F; Simón MA; Olveira A; Hernández-Guerra M; Mesquita M; Presa J; Costa-Moreira P; Macedo G; Arenas JI; Manuel Sousa J; Ampuero J; Morillas RM; Santos A; De Carvalho A; Uriz J; Carrión JA; Luisa Gutiérrez M; Pérez-Fernández E; Fernández-Rodríguez CM;
Aliment Pharmacol Ther; 2021 Feb; 53(4):519-530. PubMed ID: 33314220
[TBL] [Abstract][Full Text] [Related]
19. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]